Depression with immuno-metabolic dysregulation: Testing pragmatic criteria to stratify patients

J.C. Zwiep,Y. Milaneschi,E.J. Giltay,C.H. Vinkers,B.W.J.H. Penninx,F. Lamers
DOI: https://doi.org/10.1016/j.bbi.2024.11.033
IF: 19.227
2024-12-03
Brain Behavior and Immunity
Abstract:CONCLUSION: Our results show a dose-response relationship between both CRP levels and AES with immuno-metabolic risk biomarkers, indicating that CRP and AES combined can capture immuno-metabolic features of MDD. Combining these available and scalable indexes may be an effective strategy to select a patient sample with immuno-metabolic dysregulation who may benefit from treatments targeting inflammatory or metabolic pathways.
immunology,neurosciences,psychiatry
What problem does this paper attempt to address?